<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oral Cancer News &#187; cetuximab</title>
	<atom:link href="http://oralcancernews.org/wp/tag/cetuximab/feed/" rel="self" type="application/rss+xml" />
	<link>http://oralcancernews.org/wp</link>
	<description>The Oral Cancer Foundation News Archive</description>
	<lastBuildDate>Mon, 06 Feb 2012 22:09:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E–Mediated Anaphylaxis</title>
		<link>http://oralcancernews.org/wp/fatal-infusion-reactions-to-cetuximab-role-of-immunoglobulin-e-mediated-anaphylaxis/</link>
		<comments>http://oralcancernews.org/wp/fatal-infusion-reactions-to-cetuximab-role-of-immunoglobulin-e-mediated-anaphylaxis/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 17:24:57 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[Journal of Clinical Oncology]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12330</guid>
		<description><![CDATA[Source: Journal of Clinical Oncology To the Editor: In Journal of Clinical Oncology, Tronconi et al1 report a fatal hypersensitivity reaction to cetuximab in a 63-year-old patient with metastatic colon cancer and outlined a 0.1% incidence of death in the literature. We greatly acknowledge the authors&#8217; desire to communicate the risk of fatal anaphylactic reaction [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fatal-infusion-reactions-to-cetuximab-role-of-immunoglobulin-e-mediated-anaphylaxis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Third Head and Neck Indication for Erbitux</title>
		<link>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/</link>
		<comments>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/#comments</comments>
		<pubDate>Thu, 05 Jan 2012 18:03:40 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colorectal cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>
		<category><![CDATA[squamous cell head and neck cancer]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12267</guid>
		<description><![CDATA[Source: The ASCO Post, January 1, 2012, Volume 3, Issue 1, Matthew Stenger &#160; In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.Cetuximab (Erbitux) was recently approved by the FDA for use in combination with platinum-based therapy [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/new-indication-for-cetuximab-in-squamous-cell-carcinoma-of-the-head-and-neck/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Late-Stage Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 18:05:16 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[colon cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation therapy]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12059</guid>
		<description><![CDATA[Source: The Oncology Report The Food and Drug Administration on Nov. 7 approved cetuximab as an initial treatment of late-stage head and neck cancer in combination with chemotherapy. Cetuximab, marketed as Erbitux by Bristol-Myers Squibb, is an epidermal growth factor receptor (EGFR) antagonist, administered as an intravenous infusion. Previously, it was approved in combination with [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-late-stage-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>US FDA approval for expanded use of Erbitux</title>
		<link>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/</link>
		<comments>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/#comments</comments>
		<pubDate>Wed, 09 Nov 2011 13:24:41 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[5-fluorouracil]]></category>
		<category><![CDATA[apoptosis]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[infusion]]></category>
		<category><![CDATA[monoclonal antibody]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12055</guid>
		<description><![CDATA[Source: www.pharmabiz.com Author: staff The US Food and Drug Administration (FDA) has approved Erbitux (cetuximab), in combination with platinum-based chemotherapy with 5-fluorouracil (CT), for the first-line treatment of recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN). The approval, which is based on data from the landmark EXTREME (ErbituX in first-line [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/us-fda-approval-for-expanded-use-of-erbitux/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves Cetuximab for Metastatic Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 19:00:48 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[American Society of clinical oncology]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[radiation]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=12042</guid>
		<description><![CDATA[Source: MedScape News Today The US Food and Drug Administration (FDA) has approved cetuximab (Erbitux, Bristol-Myers Squibb ) for use in combination with chemotherapy for the treatment of metastatic head and neck cancer. Data show that when combined with cisplatin-based chemotherapy, cetuximab improved overall survival, compared with chemotherapy alone. According to the researchers, this is [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/fda-approves-cetuximab-for-metastatic-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Therapies and Prognostic Techniques Highlighted in Head and Neck Cancer</title>
		<link>http://oralcancernews.org/wp/new-therapies-and-prognostic-techniques-highlighted-in-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/new-therapies-and-prognostic-techniques-highlighted-in-head-and-neck-cancer/#comments</comments>
		<pubDate>Tue, 18 Oct 2011 16:58:29 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemoradiation]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[head and neck cancer]]></category>
		<category><![CDATA[Head and neck squamous cell carcinoma]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[laryngeal carcinoma]]></category>
		<category><![CDATA[oropharynx tumors]]></category>
		<category><![CDATA[p-16 positive head and neck squamous cell carcinoma]]></category>
		<category><![CDATA[Radiation Therapy Oncology Group]]></category>
		<category><![CDATA[thyroid cancer]]></category>
		<category><![CDATA[University of North Carolina at Chapel Hill]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11937</guid>
		<description><![CDATA[The Asco Post D. Neil Hayes, MD, MPH, of the University of North Carolina at Chapel Hill, described efforts to position the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) in head and neck cancer treatment. Surprisingly negative results came from the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial (N = 940), which showed [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/new-therapies-and-prognostic-techniques-highlighted-in-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Researchers find potential new therapeutic strategy for head and neck cancer</title>
		<link>http://oralcancernews.org/wp/researchers-find-potential-new-therapeutic-strategy-for-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/researchers-find-potential-new-therapeutic-strategy-for-head-and-neck-cancer/#comments</comments>
		<pubDate>Fri, 23 Sep 2011 23:29:08 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[ABT-888]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[DNA]]></category>
		<category><![CDATA[enzymes]]></category>
		<category><![CDATA[epidermal growth factor]]></category>
		<category><![CDATA[PARP inhibitors]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[Poly ADP-ribose polymerases]]></category>
		<category><![CDATA[receptor]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11834</guid>
		<description><![CDATA[Source: www.uab.edu Author: Beena Thannickal Shih-Hsin (Eddy) Yang, M.D., Ph.D., an assistant professor in the UAB Department of Radiation Oncology and associate scientist in the experimental therapeutics program at the UAB Comprehensive Cancer Center, found a way to prevent head and neck cancer cells from repairing damage to DNA as they grow. The findings, published [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/researchers-find-potential-new-therapeutic-strategy-for-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer drug resistance strategy uncovered</title>
		<link>http://oralcancernews.org/wp/cancer-drug-resistance-strategy-uncovered/</link>
		<comments>http://oralcancernews.org/wp/cancer-drug-resistance-strategy-uncovered/#comments</comments>
		<pubDate>Fri, 09 Sep 2011 19:20:44 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer cells]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[dana-darber cancer institute]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[science translational medicine]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11773</guid>
		<description><![CDATA[Source: Cancer Research UK Author: Staff &#160; Friday 9 September 2011- US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/cancer-drug-resistance-strategy-uncovered/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Strategy to conquer cancer drug resistance uncovered</title>
		<link>http://oralcancernews.org/wp/strategy-to-conquer-cancer-drug-resistance-uncovered/</link>
		<comments>http://oralcancernews.org/wp/strategy-to-conquer-cancer-drug-resistance-uncovered/#comments</comments>
		<pubDate>Fri, 09 Sep 2011 12:32:14 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[antibody]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[ErbB2]]></category>
		<category><![CDATA[ErbB2 inhibitors]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[resistant]]></category>
		<category><![CDATA[Trastuzumab]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11750</guid>
		<description><![CDATA[Source: info.cancerresearchuk.org Author: staff US scientists have identified a way in which cancer cells can become resistant to the cancer drug cetuximab (Erbitux), and suggest that treatments that are already available might be able to overcome this resistance. Researchers from the Dana-Farber Cancer Institute in Boston, US, have been studying why some patients only experience short-term [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/strategy-to-conquer-cancer-drug-resistance-uncovered/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypersensitivity Reactions to Erbitux Caused by Tick Bites.</title>
		<link>http://oralcancernews.org/wp/hypersensitivity-reactions-to-erbitux-caused-by-tick-bites/</link>
		<comments>http://oralcancernews.org/wp/hypersensitivity-reactions-to-erbitux-caused-by-tick-bites/#comments</comments>
		<pubDate>Fri, 01 Jul 2011 19:42:28 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[colorectal cancer]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[IgE antibody]]></category>
		<category><![CDATA[ImClone Systems]]></category>
		<category><![CDATA[tick bites]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11374</guid>
		<description><![CDATA[Source: Gastroenterology &#038; Endoscopy News Hypersensitivity reactions to cetuximab (Erbitux, ImClone Systems/Bristol-Myers Squibb), a monoclonal antibody approved for use in colorectal cancer, are not caused by the drug itself but by preexisting immunoglobulin E (IgE) antibodies that may result from tick bites, researchers have found. Cetuximab, like other monoclonal antibodies, is generally associated with a [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/hypersensitivity-reactions-to-erbitux-caused-by-tick-bites/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Yale School of Medicine Researchers take a closer look at &#8220;smart drugs&#8221;</title>
		<link>http://oralcancernews.org/wp/yale-school-of-medicine-researchers-take-a-closer-look-at-smart-drugs/</link>
		<comments>http://oralcancernews.org/wp/yale-school-of-medicine-researchers-take-a-closer-look-at-smart-drugs/#comments</comments>
		<pubDate>Thu, 19 May 2011 20:43:34 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cancer drugs]]></category>
		<category><![CDATA[cancer patients]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[Yale Cancer Center]]></category>
		<category><![CDATA[Yale School of Medicine]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11099</guid>
		<description><![CDATA[Source: Yale University Some of the most effective and expensive cancer drugs, dubbed &#8220;smart drugs&#8221; for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/yale-school-of-medicine-researchers-take-a-closer-look-at-smart-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HPV and EGFR are hottest topics in head and neck cancer</title>
		<link>http://oralcancernews.org/wp/hpv-and-egrf-are-hottest-topics-in-head-and-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/hpv-and-egrf-are-hottest-topics-in-head-and-neck-cancer/#comments</comments>
		<pubDate>Fri, 13 May 2011 14:46:08 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemoradiation]]></category>
		<category><![CDATA[cisplatin]]></category>
		<category><![CDATA[EGRF inhibitors]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[HPV]]></category>
		<category><![CDATA[human papillomavirus]]></category>
		<category><![CDATA[panitumumab]]></category>
		<category><![CDATA[prognosis]]></category>
		<category><![CDATA[radiotherapy]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=11050</guid>
		<description><![CDATA[Source: www.medscape.com Author: Zosia Chustecka The hottest topic in head and neck cancers is the role of human papillomavirus (HPV) in the disease, although there is also a lot interest in treatment with EGRF inhibitors, especially the second-generation products, according to an expert here at the European Society for Therapeutic Radiology and Oncology 11th Biennial [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/hpv-and-egrf-are-hottest-topics-in-head-and-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data</title>
		<link>http://oralcancernews.org/wp/cetuximab-therapy-for-head-and-neck-squamous-cell-carcinoma-a-systematic-review-of-the-data/</link>
		<comments>http://oralcancernews.org/wp/cetuximab-therapy-for-head-and-neck-squamous-cell-carcinoma-a-systematic-review-of-the-data/#comments</comments>
		<pubDate>Sat, 05 Mar 2011 19:32:58 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Head and neck squamous cell carcinoma]]></category>
		<category><![CDATA[HNSCC]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10624</guid>
		<description><![CDATA[Source: http://oto.sagepub.com/ Authors: Travis D. Reeves, MD et al. Objective: To review the current state of the data on the use of cetuximab in head and neck squamous cell carcinoma (HNSCC). Data Sources: The National Center for Biotechnology Information’s PubMed and the Cochrane collection. Review Methods. Search terms included cetuximab and head and neck cancer. [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/cetuximab-therapy-for-head-and-neck-squamous-cell-carcinoma-a-systematic-review-of-the-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Rash prediction in lung cancer?</title>
		<link>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/</link>
		<comments>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 15:09:24 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[rash]]></category>
		<category><![CDATA[survival]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=10317</guid>
		<description><![CDATA[Source: www.medscape.com Author: Maurie Markman, MD Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss with you a very interesting paper[1] that appeared online in The Lancet Oncology on December 20th, 2010, and will be in print soon. The paper was entitled &#8220;First-Cycle Rash and [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/rash-prediction-in-lung-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ASCO: Non-platinum regimen works in head, neck cancer</title>
		<link>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/</link>
		<comments>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/#comments</comments>
		<pubDate>Sun, 06 Jun 2010 14:32:19 +0000</pubDate>
		<dc:creator>Oral Cancer Foundation News Team - A</dc:creator>
				<category><![CDATA[Oral Cancer News]]></category>
		<category><![CDATA[alimta]]></category>
		<category><![CDATA[Avastin]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[erbitux]]></category>
		<category><![CDATA[monoclonal antibody]]></category>
		<category><![CDATA[pemetrexed]]></category>
		<category><![CDATA[vascular epithelial growth factor]]></category>
		<category><![CDATA[VEGF]]></category>

		<guid isPermaLink="false">http://oralcancernews.org/wp/?p=8806</guid>
		<description><![CDATA[Source: www.medpagetoday.com Author: Michael Smith, North American Correspondent, MedPage Today A novel non-platinum-based regimen was efficacious in recurrent or metastatic squamous cell head and neck cancer, researchers said. The combination of pemetrexed (Alimta) and bevacizumab (Avastin) yielded a response rate of 30% in a small single-arm trial, according to Athanassios Argiris, MD, of the University [...]]]></description>
		<wfw:commentRss>http://oralcancernews.org/wp/asco-non-platinum-regimen-works-in-head-neck-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

